Business Context and Reporting Period
Company: Novartis AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2004
Release Date: April 22, 2004
Overview: Novartis reported strong double-digit sales growth and robust gains in operating and net income, driven by the dynamic performance of its young pharmaceutical product portfolio and the consolidation of the Mead Johnson Medical Nutrition acquisition.
Key Financial Metrics
| Metric (USD millions) | Q1 2004 | Q1 2003 | % Change (USD) | % Change (Local Currency) |
|---|---|---|---|---|
| Group Sales | 6,639 | 5,721 | 16% | 8% |
| Pharmaceuticals Sales | 4,310 | 3,609 | 19% | 11% |
| Consumer Health Sales | 2,329 | 2,112 | 10% | 2% |
| Operating Income | 1,494 | 1,351 | 11% | - |
| Operating Margin | 22.5% | 23.6% | - | - |
| Net Income | 1,293 | 1,063 | 22% | - |
| Earnings Per Share (Diluted) | $0.52 | $0.42 | 24% | - |
| Free Cash Flow | (1,064) | (66) | - | - |
| Net Liquidity | 5,562 | 7,017 | - | - |
| Debt/Equity Ratio | 0.22:1 | 0.20:1 | - | - |
Material Changes vs. Prior Period
- Sales Growth: Group sales increased 16% (8% in local currencies). Pharmaceuticals sales rose 19% (11% lc), while Consumer Health grew 10% (2% lc). Volume expansion of 5% was the primary driver of local currency growth.
- Profitability: Operating income grew 11% to $1.5 billion despite high R&D investments. Net income surged 22% to $1.3 billion, aided by improved performance of the Roche investment.
- Cost Structure: Cost of Goods Sold (COGS) declined to 23.1% of sales. Marketing & Sales costs grew 12% in USD but decreased as a percentage of sales to 31.0%. R&D costs increased 12% due to the build-up of the Novartis Institutes for Biomedical Research (NIBR).
- Cash Flow: Free cash flow decreased significantly by $998 million compared to the prior year, primarily due to a $244 million increase in dividend payments and a $597 million reduction in operating cash flow caused by a $705 million withholding tax payment on dividends.
- Balance Sheet: Total equity decreased by $1.1 billion to $29.3 billion due to dividend payments ($2.0 billion), treasury share purchases ($0.3 billion), and translation losses ($0.3 billion), partially offset by net income.
Guidance, Outlook, and Risks
- Outlook: Management expects to outpace the market with high single-digit sales growth in local currencies for the full year. Full-year operating and net income are expected to exceed 2003 levels, barring unforeseen events.
- Strategic Drivers: Growth is expected to be driven by seven pharmaceutical brands forecast to become blockbusters by 2008 and a rich late-stage pipeline. The NIBR facility build-up is scheduled for completion in 2004.
- Transaction with Aventis: The Board has accepted an offer to negotiate conditions for a potential business combination with Aventis. No assurances can be given that an agreement will be reached.
- Risks: Forward-looking statements are subject to risks including new clinical data, unexpected trial results, regulatory delays, patent protection issues, competition, and government pricing pressures.
Investor Verification Checklist
- Aventis Negotiations: Verify the status and potential terms of the business combination talks with Aventis, as this could materially alter the company's structure.
- Product Pipeline: Confirm the progress of the ten new medicines in late-stage development, specifically LAF237, SPP100, and Zelmac/Zelnorm FD which entered Phase III trials.
- Cash Flow Volatility: Review the impact of the $705 million withholding tax payment on operating cash flow to understand the timing of future dividend-related cash outflows.
- Regulatory Approvals: Monitor the status of new indications for Diovan (post-myocardial infarction) and Certican (transplantation) in key markets like the US and Europe.
- Share Repurchases: Track the continuation of the share repurchase program, which has totaled $2.1 billion since July 2002, including $188 million in Q1 2004.